Experimental cell therapy tested for Tough-to-Treat blood cancers
NCT ID NCT04620681
Summary
This study tested the safety of an experimental cell therapy for patients with advanced myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) after their initial treatment stopped working. The therapy involved infusing specially prepared immune cells from an unrelated donor. The goal was to see if this approach could help control the disease and was safe enough for further testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.